Market Highlights

• Abzena has expanded its quality control capabilities at its San Diego site, adding advanced microbiology testing and materials separation to meet growing regulatory demands and support scalable biopharmaceutical innovations.
• San Diego based Maravai LifeSciences announced plans to acquire Officinae Bio's DNA and RNA business, strengthening its support for nucleic acid-based therapy development.
• Venture capital funding in San Diego grew 63.0% from the end of 2023 to the end of 2024, with Angitia Biopharmaceuticals leading the final quarter by raising $120.0 million.

Read the full report